You are here: Home » Reuters » News
Business Standard

Celgene to buy Impact Biomedicines for up to $7 billion

Reuters  |  NEW YORK 

NEW YORK (Reuters) - U.S. biotech pharmaceutical firm Celgene Corp said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.Celgene is interested in Impact Biomedicines' fedratinib, a kinase inhibitor that has shown promise as a potential treatment for a type of blood cancer called myelofibrosis, according to a statement put out jointly by both companies."Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, January 08 2018. 08:57 IST
RECOMMENDED FOR YOU